SCHEMBL456579

SCHEMBL456579

O=C(O)c1ccc(NC(=S)NN=C2Nc3ccccc3C2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
RAB9A P51151 3/20 0.44
TDP1 Q9NUW8 3/20 0.44
NPC1 O15118 2/20 0.44
KMT2A Q03164 6/20 0.43
NPSR1 Q6W5P4 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
MEN1 O00255 4/20 0.43
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
PIM1 P11309 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
KDR P35968 1/20 0.40
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HK1 P19367 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877739 0.86 MAPT (0.51) ALDH1A1RAB9ATDP1NPC1KMT2A
SCHEMBL2877863 0.86 ALDH1A1 (0.46) ALDH1A1RAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL455695 0.83 SLC2A1 (0.44) ALDH1A1RAB9ATDP1NPC1KMT2A
SCHEMBL456608 0.83 CYP1A2 (0.49) ALDH1A1RAB9ATDP1NPC1KMT2A
SCHEMBL456909 0.83 BCHE (0.43) ALDH1A1RAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL455312 0.83 MAPT (0.42) ALDH1A1TDP1NPC1KMT2ANPSR1
SCHEMBL455238 0.83 RAB9A (0.44) ALDH1A1RAB9ATDP1NPC1SMN1; SMN2
SCHEMBL457421 0.83 LRRK2 (0.42) ALDH1A1RAB9ATDP1NPC1KMT2A
SCHEMBL455700 0.82 ALDH1A1 (0.47) ALDH1A1TDP1NPC1KMT2ANPSR1
SCHEMBL456638 0.79 MAOA (0.34) ALDH1A1RAB9ATDP1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed